Safety, pharmacokinetics and exploratory exposure-response analysis of CX3002, a novel inhibitor of Xa, in Chinese healthy subjects-Reference-Cited by-同舟云学术

Safety, pharmacokinetics and exploratory exposure-response analysis of CX3002, a novel inhibitor of Xa, in Chinese healthy subjects

Published:2023-06 Issue: Volume:185 Page:106437
ISSN:0928-0987
Container-title:European Journal of Pharmaceutical Sciences
language:en
Short-container-title:European Journal of Pharmaceutical Sciences

Author:

Chen Wenjun,Ruan Zourong,Lou Honggang,Wang Lu,Shao Rong,Li Fenghua,Jiang Bo

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference27 articles.

1. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay;Barrett;Thromb. Haemost.,2010

2. Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism;Byon;CPT Pharmacomet. Syst. Pharmacol.,2017

3. Apixaban: a clinical pharmacokinetic and pharmacodynamic review;Byon;Clin. Pharmacokinet.,2019

4. Population pharmacokinetics of apixaban in subjects with nonvalvular atrial fibrillation;Cirincione;CPT Pharmacomet. Syst. Pharmacol.,2018

5. European Medicines Agency, 2022. Eliquis–Summary of Product Characteristics. Available online: https://www.ema.europa.eu/en/documents/product-information/eliquis-epar-product-information_en.pdf. Last accessed 2023 Mar 18.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis on dynamic changes of etizolam and its metabolites and exploration of its development prospect using UPLC-Q-exactive-MS;Journal of Pharmaceutical and Biomedical Analysis;2024-03